Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2...
Gespeichert in:
| Veröffentlicht in: | Primary care diabetes 2023-08, Vol.17 (4), p.366-372 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 372 |
|---|---|
| container_issue | 4 |
| container_start_page | 366 |
| container_title | Primary care diabetes |
| container_volume | 17 |
| creator | Seijas-Amigo, José Salgado-Barreira, Ángel Castelo-Dominguez, Rosana Pérez-Álvarez, María Teresa Ponce-Piñón, Belén Fernández-Silva, Marlén Rodríguez-Barreiro, Marta Pereira-Pía, Mercedes Iglesias-Moreno, Jose Manuel Gago-García, Mar Montáns-García, Raquel Fernandez-Perez, Agustina FragaGayoso, Dolores Fernandez-Montenegro, Montse Riveiro-Barciela, Beatriz Rilla-Villar, Natalia Cordero, Alberto RodríguezMañero, Moisés González-Juanatey, José R. |
| description | Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.
It is a multicenter, prospective, and observational study on GLP1 RA naïve patients. The primary end point was the weight loss (≥5 %). Changes in weight, BMI and HbA1c were also calculated as co-primary endpoints. Secondary endpoints were safety, adherence, and tolerance.
Among 94 subjects, 42.4 % received dulaglutide, 29,3 % subcutaneous semaglutide, 22,8 % oral semaglutide. 45 % female and the mean age was 62. Baseline characteristics were body weight 99.3 kg, BMI 36.7 kg/m2 and Hba1c 8.2 %. Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %. GLP1 RA significantly reduced body weight (−4.95 kg, p |
| doi_str_mv | 10.1016/j.pcd.2023.05.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2820025569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1751991823000955</els_id><sourcerecordid>2820025569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-fe1ef1710974f98188bd4c66a8e25ab78494442a64bb8796624428191b5130813</originalsourceid><addsrcrecordid>eNp9kcFu1DAURSMEoqXwAWyQl2wS_JzEcWBVFQpIlbopa8uxX2Y8JHawnVbTL-Fz6-mULln5Wb7vSL6nKN4DrYAC_7SrFm0qRlld0baitHlRnILoREkZ0Jd57loo-x7ESfEmxh2lHGrRvS5O6o7VVEB9Wvz9ascRAzqNkVhH7tButolMPkainCFRjZj2ZMB0h-hI2iLZTKtWG-_Kyf5GsuCSrMESSECdZx_I4dHGFD-Tc-JyLmSQn-09GjKvU7IaXcJAYlrNnozBz4_YZFNQyXpHlq2K-LZ4Naop4run86z4dfnt5uJHeXX9_efF-VWp656nckTAETqgfdeMvQAhBtNozpVA1qqhE03fNA1TvBkG0fWcs3wT0MPQwmMFZ8XHI3cJ_s-KMcnZRo3TpBz6NUomGKWsbXmfo3CM6pDrCTjKJdhZhb0EKg9C5E5mIfIgRNJWZiF558MTfh1mNM8b_wzkwJdjAPMnby0GGbU96DA2F5qk8fY_-AcUW50V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820025569</pqid></control><display><type>article</type><title>Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase</title><source>Access via ScienceDirect (Elsevier)</source><creator>Seijas-Amigo, José ; Salgado-Barreira, Ángel ; Castelo-Dominguez, Rosana ; Pérez-Álvarez, María Teresa ; Ponce-Piñón, Belén ; Fernández-Silva, Marlén ; Rodríguez-Barreiro, Marta ; Pereira-Pía, Mercedes ; Iglesias-Moreno, Jose Manuel ; Gago-García, Mar ; Montáns-García, Raquel ; Fernandez-Perez, Agustina ; FragaGayoso, Dolores ; Fernandez-Montenegro, Montse ; Riveiro-Barciela, Beatriz ; Rilla-Villar, Natalia ; Cordero, Alberto ; RodríguezMañero, Moisés ; González-Juanatey, José R.</creator><creatorcontrib>Seijas-Amigo, José ; Salgado-Barreira, Ángel ; Castelo-Dominguez, Rosana ; Pérez-Álvarez, María Teresa ; Ponce-Piñón, Belén ; Fernández-Silva, Marlén ; Rodríguez-Barreiro, Marta ; Pereira-Pía, Mercedes ; Iglesias-Moreno, Jose Manuel ; Gago-García, Mar ; Montáns-García, Raquel ; Fernandez-Perez, Agustina ; FragaGayoso, Dolores ; Fernandez-Montenegro, Montse ; Riveiro-Barciela, Beatriz ; Rilla-Villar, Natalia ; Cordero, Alberto ; RodríguezMañero, Moisés ; González-Juanatey, José R.</creatorcontrib><description>Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.
It is a multicenter, prospective, and observational study on GLP1 RA naïve patients. The primary end point was the weight loss (≥5 %). Changes in weight, BMI and HbA1c were also calculated as co-primary endpoints. Secondary endpoints were safety, adherence, and tolerance.
Among 94 subjects, 42.4 % received dulaglutide, 29,3 % subcutaneous semaglutide, 22,8 % oral semaglutide. 45 % female and the mean age was 62. Baseline characteristics were body weight 99.3 kg, BMI 36.7 kg/m2 and Hba1c 8.2 %. Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %. GLP1 RA significantly reduced body weight (−4.95 kg, p < 0.001) and BMI (−1.86 kg/m2, p < 0.001), without significant differences between groups. Gastrointestinal disorders were the most frequently reported events (74.5 %). 62 % of patients on dulaglutide, 25 % on oral semaglutide and 22 % on subcutaneous semaglutide.
Oral semaglutide achieved the highest proportion of patients that lost ≥ 5 %. GLP1 RA significantly reduced BMI and HbA1c. Most of the reported adverse events were gastrointestinal disorders and they were reported in a major frequency in the dulaglutide group. Oral semaglutide would be a reasonable switch in case of future shortages.
•Oral semaglutide achieved the highest reduction: 61.1 % (≥5 %).•New safety information during the up-titration is provided.•Most of the gastrointestinal events were on dulaglutide group (14 %)•Oral semaglutide would be a reasonable switch during this shortage period.</description><identifier>ISSN: 1751-9918</identifier><identifier>EISSN: 1878-0210</identifier><identifier>DOI: 10.1016/j.pcd.2023.05.004</identifier><identifier>PMID: 37230813</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adherence ; Glucagon-like peptide 1 ; Glycemic control ; Obesity ; Safety ; Type 2 diabetes ; Weight change</subject><ispartof>Primary care diabetes, 2023-08, Vol.17 (4), p.366-372</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-fe1ef1710974f98188bd4c66a8e25ab78494442a64bb8796624428191b5130813</citedby><cites>FETCH-LOGICAL-c396t-fe1ef1710974f98188bd4c66a8e25ab78494442a64bb8796624428191b5130813</cites><orcidid>0000-0003-4349-4947</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pcd.2023.05.004$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37230813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seijas-Amigo, José</creatorcontrib><creatorcontrib>Salgado-Barreira, Ángel</creatorcontrib><creatorcontrib>Castelo-Dominguez, Rosana</creatorcontrib><creatorcontrib>Pérez-Álvarez, María Teresa</creatorcontrib><creatorcontrib>Ponce-Piñón, Belén</creatorcontrib><creatorcontrib>Fernández-Silva, Marlén</creatorcontrib><creatorcontrib>Rodríguez-Barreiro, Marta</creatorcontrib><creatorcontrib>Pereira-Pía, Mercedes</creatorcontrib><creatorcontrib>Iglesias-Moreno, Jose Manuel</creatorcontrib><creatorcontrib>Gago-García, Mar</creatorcontrib><creatorcontrib>Montáns-García, Raquel</creatorcontrib><creatorcontrib>Fernandez-Perez, Agustina</creatorcontrib><creatorcontrib>FragaGayoso, Dolores</creatorcontrib><creatorcontrib>Fernandez-Montenegro, Montse</creatorcontrib><creatorcontrib>Riveiro-Barciela, Beatriz</creatorcontrib><creatorcontrib>Rilla-Villar, Natalia</creatorcontrib><creatorcontrib>Cordero, Alberto</creatorcontrib><creatorcontrib>RodríguezMañero, Moisés</creatorcontrib><creatorcontrib>González-Juanatey, José R.</creatorcontrib><title>Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase</title><title>Primary care diabetes</title><addtitle>Prim Care Diabetes</addtitle><description>Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.
It is a multicenter, prospective, and observational study on GLP1 RA naïve patients. The primary end point was the weight loss (≥5 %). Changes in weight, BMI and HbA1c were also calculated as co-primary endpoints. Secondary endpoints were safety, adherence, and tolerance.
Among 94 subjects, 42.4 % received dulaglutide, 29,3 % subcutaneous semaglutide, 22,8 % oral semaglutide. 45 % female and the mean age was 62. Baseline characteristics were body weight 99.3 kg, BMI 36.7 kg/m2 and Hba1c 8.2 %. Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %. GLP1 RA significantly reduced body weight (−4.95 kg, p < 0.001) and BMI (−1.86 kg/m2, p < 0.001), without significant differences between groups. Gastrointestinal disorders were the most frequently reported events (74.5 %). 62 % of patients on dulaglutide, 25 % on oral semaglutide and 22 % on subcutaneous semaglutide.
Oral semaglutide achieved the highest proportion of patients that lost ≥ 5 %. GLP1 RA significantly reduced BMI and HbA1c. Most of the reported adverse events were gastrointestinal disorders and they were reported in a major frequency in the dulaglutide group. Oral semaglutide would be a reasonable switch in case of future shortages.
•Oral semaglutide achieved the highest reduction: 61.1 % (≥5 %).•New safety information during the up-titration is provided.•Most of the gastrointestinal events were on dulaglutide group (14 %)•Oral semaglutide would be a reasonable switch during this shortage period.</description><subject>Adherence</subject><subject>Glucagon-like peptide 1</subject><subject>Glycemic control</subject><subject>Obesity</subject><subject>Safety</subject><subject>Type 2 diabetes</subject><subject>Weight change</subject><issn>1751-9918</issn><issn>1878-0210</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAURSMEoqXwAWyQl2wS_JzEcWBVFQpIlbopa8uxX2Y8JHawnVbTL-Fz6-mULln5Wb7vSL6nKN4DrYAC_7SrFm0qRlld0baitHlRnILoREkZ0Jd57loo-x7ESfEmxh2lHGrRvS5O6o7VVEB9Wvz9ascRAzqNkVhH7tButolMPkainCFRjZj2ZMB0h-hI2iLZTKtWG-_Kyf5GsuCSrMESSECdZx_I4dHGFD-Tc-JyLmSQn-09GjKvU7IaXcJAYlrNnozBz4_YZFNQyXpHlq2K-LZ4Naop4run86z4dfnt5uJHeXX9_efF-VWp656nckTAETqgfdeMvQAhBtNozpVA1qqhE03fNA1TvBkG0fWcs3wT0MPQwmMFZ8XHI3cJ_s-KMcnZRo3TpBz6NUomGKWsbXmfo3CM6pDrCTjKJdhZhb0EKg9C5E5mIfIgRNJWZiF558MTfh1mNM8b_wzkwJdjAPMnby0GGbU96DA2F5qk8fY_-AcUW50V</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Seijas-Amigo, José</creator><creator>Salgado-Barreira, Ángel</creator><creator>Castelo-Dominguez, Rosana</creator><creator>Pérez-Álvarez, María Teresa</creator><creator>Ponce-Piñón, Belén</creator><creator>Fernández-Silva, Marlén</creator><creator>Rodríguez-Barreiro, Marta</creator><creator>Pereira-Pía, Mercedes</creator><creator>Iglesias-Moreno, Jose Manuel</creator><creator>Gago-García, Mar</creator><creator>Montáns-García, Raquel</creator><creator>Fernandez-Perez, Agustina</creator><creator>FragaGayoso, Dolores</creator><creator>Fernandez-Montenegro, Montse</creator><creator>Riveiro-Barciela, Beatriz</creator><creator>Rilla-Villar, Natalia</creator><creator>Cordero, Alberto</creator><creator>RodríguezMañero, Moisés</creator><creator>González-Juanatey, José R.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4349-4947</orcidid></search><sort><creationdate>202308</creationdate><title>Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase</title><author>Seijas-Amigo, José ; Salgado-Barreira, Ángel ; Castelo-Dominguez, Rosana ; Pérez-Álvarez, María Teresa ; Ponce-Piñón, Belén ; Fernández-Silva, Marlén ; Rodríguez-Barreiro, Marta ; Pereira-Pía, Mercedes ; Iglesias-Moreno, Jose Manuel ; Gago-García, Mar ; Montáns-García, Raquel ; Fernandez-Perez, Agustina ; FragaGayoso, Dolores ; Fernandez-Montenegro, Montse ; Riveiro-Barciela, Beatriz ; Rilla-Villar, Natalia ; Cordero, Alberto ; RodríguezMañero, Moisés ; González-Juanatey, José R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-fe1ef1710974f98188bd4c66a8e25ab78494442a64bb8796624428191b5130813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adherence</topic><topic>Glucagon-like peptide 1</topic><topic>Glycemic control</topic><topic>Obesity</topic><topic>Safety</topic><topic>Type 2 diabetes</topic><topic>Weight change</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seijas-Amigo, José</creatorcontrib><creatorcontrib>Salgado-Barreira, Ángel</creatorcontrib><creatorcontrib>Castelo-Dominguez, Rosana</creatorcontrib><creatorcontrib>Pérez-Álvarez, María Teresa</creatorcontrib><creatorcontrib>Ponce-Piñón, Belén</creatorcontrib><creatorcontrib>Fernández-Silva, Marlén</creatorcontrib><creatorcontrib>Rodríguez-Barreiro, Marta</creatorcontrib><creatorcontrib>Pereira-Pía, Mercedes</creatorcontrib><creatorcontrib>Iglesias-Moreno, Jose Manuel</creatorcontrib><creatorcontrib>Gago-García, Mar</creatorcontrib><creatorcontrib>Montáns-García, Raquel</creatorcontrib><creatorcontrib>Fernandez-Perez, Agustina</creatorcontrib><creatorcontrib>FragaGayoso, Dolores</creatorcontrib><creatorcontrib>Fernandez-Montenegro, Montse</creatorcontrib><creatorcontrib>Riveiro-Barciela, Beatriz</creatorcontrib><creatorcontrib>Rilla-Villar, Natalia</creatorcontrib><creatorcontrib>Cordero, Alberto</creatorcontrib><creatorcontrib>RodríguezMañero, Moisés</creatorcontrib><creatorcontrib>González-Juanatey, José R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Primary care diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seijas-Amigo, José</au><au>Salgado-Barreira, Ángel</au><au>Castelo-Dominguez, Rosana</au><au>Pérez-Álvarez, María Teresa</au><au>Ponce-Piñón, Belén</au><au>Fernández-Silva, Marlén</au><au>Rodríguez-Barreiro, Marta</au><au>Pereira-Pía, Mercedes</au><au>Iglesias-Moreno, Jose Manuel</au><au>Gago-García, Mar</au><au>Montáns-García, Raquel</au><au>Fernandez-Perez, Agustina</au><au>FragaGayoso, Dolores</au><au>Fernandez-Montenegro, Montse</au><au>Riveiro-Barciela, Beatriz</au><au>Rilla-Villar, Natalia</au><au>Cordero, Alberto</au><au>RodríguezMañero, Moisés</au><au>González-Juanatey, José R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase</atitle><jtitle>Primary care diabetes</jtitle><addtitle>Prim Care Diabetes</addtitle><date>2023-08</date><risdate>2023</risdate><volume>17</volume><issue>4</issue><spage>366</spage><epage>372</epage><pages>366-372</pages><issn>1751-9918</issn><eissn>1878-0210</eissn><abstract>Obesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.
It is a multicenter, prospective, and observational study on GLP1 RA naïve patients. The primary end point was the weight loss (≥5 %). Changes in weight, BMI and HbA1c were also calculated as co-primary endpoints. Secondary endpoints were safety, adherence, and tolerance.
Among 94 subjects, 42.4 % received dulaglutide, 29,3 % subcutaneous semaglutide, 22,8 % oral semaglutide. 45 % female and the mean age was 62. Baseline characteristics were body weight 99.3 kg, BMI 36.7 kg/m2 and Hba1c 8.2 %. Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %. GLP1 RA significantly reduced body weight (−4.95 kg, p < 0.001) and BMI (−1.86 kg/m2, p < 0.001), without significant differences between groups. Gastrointestinal disorders were the most frequently reported events (74.5 %). 62 % of patients on dulaglutide, 25 % on oral semaglutide and 22 % on subcutaneous semaglutide.
Oral semaglutide achieved the highest proportion of patients that lost ≥ 5 %. GLP1 RA significantly reduced BMI and HbA1c. Most of the reported adverse events were gastrointestinal disorders and they were reported in a major frequency in the dulaglutide group. Oral semaglutide would be a reasonable switch in case of future shortages.
•Oral semaglutide achieved the highest reduction: 61.1 % (≥5 %).•New safety information during the up-titration is provided.•Most of the gastrointestinal events were on dulaglutide group (14 %)•Oral semaglutide would be a reasonable switch during this shortage period.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37230813</pmid><doi>10.1016/j.pcd.2023.05.004</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4349-4947</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1751-9918 |
| ispartof | Primary care diabetes, 2023-08, Vol.17 (4), p.366-372 |
| issn | 1751-9918 1878-0210 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2820025569 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Adherence Glucagon-like peptide 1 Glycemic control Obesity Safety Type 2 diabetes Weight change |
| title | Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A39%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20weight%20loss%20and%20safety%20between%20the%20glucagon-like%20peptide-1%20receptor%20agonists:%20A%20non-randomized%20multicenter%20study%20from%20the%20titration%20phase&rft.jtitle=Primary%20care%20diabetes&rft.au=Seijas-Amigo,%20Jos%C3%A9&rft.date=2023-08&rft.volume=17&rft.issue=4&rft.spage=366&rft.epage=372&rft.pages=366-372&rft.issn=1751-9918&rft.eissn=1878-0210&rft_id=info:doi/10.1016/j.pcd.2023.05.004&rft_dat=%3Cproquest_cross%3E2820025569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2820025569&rft_id=info:pmid/37230813&rft_els_id=S1751991823000955&rfr_iscdi=true |